Kodiak Sciences Inc

+0.51 (+0.66%)
Products, Regulatory

Kodiak Sciences Treats First Patients In Three Phase 3 Studies Of KSI-301

Published: 10/05/2020 17:17 GMT
Kodiak Sciences Inc (KOD) - Kodiak Sciences Treats First Patients in Three Phase 3 Studies of Ksi-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion.
Kodiak Sciences Inc - Also Announces Completion of U.S. Patient Enrollment in Dazzle, Its Ongoing Phase 2b/3 Study of Ksi-301 in Wet Amd.
Kodiak Sciences Inc - Phase 1b Durability Data Continue to Improve As They Mature Further.
Kodiak Sciences - 72% of Wet Amd Patients & 79% of Dme Patients Achieved 6-month Or Longer Treatment Free Interval at Least Once During Follow-up.
Kodiak Sciences Inc - 81% of Rvo Patients Have Achieved a 4-month Or Longer Interval.